百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BGNE 百济神州

交易中 04-24 12:41:48 EDT

142.08

+3.09

+2.22%

最高146.22	最低141.78	成交量10.41万
今开143.48	昨收138.99	日振幅3.19%
总市值148.45亿	流通市值83.27亿	总股本1.04亿
成交额1,497万	换手率0.18%	流通股本5,861万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":142.075,"timestamp":1713976690059,"preClose":138.99,"halted":0,"volume":104070,"delay":0,"floatShares":58607752,"shares":104490318,"eps":-8.446508,"marketStatus":"交易中","marketStatusCode":2,"change":3.085,"latestTime":"04-24 12:41:48 EDT","open":143.48,"high":146.22,"low":141.78,"amount":14967979.104899999,"amplitude":0.031945,"askPrice":142.24,"askSize":23,"bidPrice":141.85,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-8.446508,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713988800000},"adr":1,"adjPreClose":138.99,"adrRate":13,"preHourTrading":{"tag":"盘前","latestPrice":143.45,"preClose":138.99,"latestTime":"09:29 EDT","volume":713,"amount":102601.64116,"timestamp":1713965399999},"postHourTrading":{"tag":"盘后","latestPrice":138.99,"preClose":138.99,"latestTime":"16:06 EDT","volume":1840,"amount":255738.11,"timestamp":1713902799468},"volumeRatio":1.080071},"requestUrl":"/m/hq/s/BGNE?invite=TIGER026","defaultTab":"news","newsList":[{"id":"2429456166","title":"百济神州上涨3.23%，报143.48美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429456166","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429456166?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:30","pubTimestamp":1713965432,"startTime":"0","endTime":"0","summary":"4月24日，百济神州(BGNE)开盘上涨3.23%，截至21:30，报143.48美元/股，成交76.59万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：5月2日，百济神州将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24213040392874.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429253177","title":"港股异动 | 百济神州(06160)涨近4% 替雷利珠单抗获欧盟委员会批准用于治疗非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2429253177","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429253177?lang=zh_cn&edition=full","pubTime":"2024-04-24 11:31","pubTimestamp":1713929479,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州(06160)涨近4%，截至发稿，涨3.54%，报84.9港元，成交额4813.84万港元。消息面上，百济神州宣布欧盟委员会（EC）已批准替雷利珠单抗用于三项非小细胞肺癌（NSCLC）适应症的一线及二线治疗。被批准用于上述NSCLC适应症的替雷利珠单抗商品名为TIZVENI®。公司计划将NSCLC适应症与ESCC二线治疗适应症统一合并至商品名TEVIMBRA®下，TEVIMBRA®将于今年晚些时候在首批欧盟国家上市。目前，百济神州已启动超过17项替雷利珠单抗的潜在注册性研究，其中，11项3期随机对照研究和4项2期研究均获得积极数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108261.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429419022","title":"百济神州盘中异动 早盘快速拉升5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429419022","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429419022?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:30","pubTimestamp":1713879042,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日21时30分，百济神州股票出现异动，股价急速拉升5.17%。截至发稿，该股报137.71美元/股，成交量1962股，换手率0.00%，振幅0.00%。机构评级方面，在所有25家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为1.18%。百济神州公司简介：百济神州有限公司是一家处于商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232130437922aeaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232130437922aeaa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164082","title":"百济神州(688235.SH)：欧盟委员会批准百泽安®用于3项非小细胞肺癌适应症的一线及二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164082","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429164082?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:18","pubTimestamp":1713867537,"startTime":"0","endTime":"0","summary":"EGFR突变或ALK突变阳性的NSCLC患者在接受替雷利珠单抗治疗前应当已接受过靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107680.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429640971","title":"百济神州替雷利珠单抗获欧盟委员会批准用于治疗非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2429640971","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2429640971?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:05","pubTimestamp":1713866700,"startTime":"0","endTime":"0","summary":"此次EC的决定标志着替雷利珠单抗在该地区获得第二项批准，在欧盟地区，替雷利珠单抗可用于治疗NSCLC和局部晚期或转移性食管鳞状细胞癌。EGFR突变或ALK突变阳性的NSCLC患者在接受替雷利珠单抗治疗前应当已接受过靶向治疗。迄今为止，替雷利珠单抗已惠及超过90万全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4392423_ZH92423_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429872531","title":"南向资金4月22日净买入百济神州25.34万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429872531","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429872531?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:31","pubTimestamp":1713835874,"startTime":"0","endTime":"0","summary":"4月22日, 南向资金增持百济神州25.34万股，连续3日增持。截止当日收盘，港股通共持有百济神州5257.94万股，占流通股3.85%。百济神州近5个交易日下跌5.18%，港股通累计增持31.63万股；近20个交易日下跌22.37%，港股通累计增持216.90万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309473187a38916&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309473187a38916&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428520381","title":"百济神州获融资买入0.13亿元，近三日累计买入0.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428520381","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428520381?lang=zh_cn&edition=full","pubTime":"2024-04-19 08:21","pubTimestamp":1713486102,"startTime":"0","endTime":"0","summary":"4月18日，沪深两融数据显示，百济神州获融资买入额0.13亿元，居两市第601位，当日融资偿还额0.06亿元，净买入707.20万元。最近三个交易日，16日-18日，百济神州分别获融资买入0.06亿元、0.10亿元、0.13亿元。融券方面，当日融券卖出0.54万股，净买入0.59万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190821478792723c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190821478792723c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428058981","title":"营收达178亿，百济神州逆势加码！创新药的春天来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2428058981","media":"侃见财经","top":-1,"share":"https://www.laohu8.com/m/news/2428058981?lang=zh_cn&edition=full","pubTime":"2024-04-18 10:04","pubTimestamp":1713405851,"startTime":"0","endTime":"0","summary":"且在27家生物医药类的上市公司当中，仅有8家公司IPO募资金额超过了10亿元。百济神州在年报中提到，公司营业收入增加主要得益于核心市场产品销售额的增长。其中百悦泽全球销售额达13亿美元，突破十亿美元大关。值得注意的是，百悦泽的成功，让百济神州成功的摆脱了资金困境，根据财报显示，截至2023年末公司期末现金、现金等价物及受限现金31.86亿美元。受此影响，百济神州的股价在创新药行业当中，一直比较坚挺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418100944878cb300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418100944878cb300&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428583817","title":"北向资金4月17日净买入百济神州-U4.82万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428583817","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428583817?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:30","pubTimestamp":1713403830,"startTime":"0","endTime":"0","summary":"4月17日, 北向资金增持百济神州-U4.82万股，连续5日增持。截止当日收盘，沪股通共持有百济神州-U538.87万股，占流通股4.68%。沪股通增持金额前五个股分别为国电电力、大秦铁路、同仁堂、中国平安、赤峰黄金。百济神州-U近5个交易日下跌8.50%，沪股通累计增持12.65万股；近20个交易日下跌14.09%，沪股通累计增持47.74万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180935218b3248a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180935218b3248a0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427850430","title":"南向资金4月15日净买入百济神州23.99万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427850430","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427850430?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:31","pubTimestamp":1713231090,"startTime":"0","endTime":"0","summary":"4月15日, 南向资金增持百济神州23.99万股，连续3日增持。截止当日收盘，港股通共持有百济神州5226.30万股，占流通股3.84%。百济神州近5个交易日下跌6.72%，港股通累计增持27.33万股；近20个交易日下跌19.00%，港股通累计增持364.33万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160943538781e7cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160943538781e7cf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427850259","title":"北向资金4月15日净买入百济神州-U1.57万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427850259","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427850259?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:30","pubTimestamp":1713231036,"startTime":"0","endTime":"0","summary":"4月15日, 北向资金增持百济神州-U1.57万股，连续3日增持。截止当日收盘，沪股通共持有百济神州-U531.20万股，占流通股4.61%。沪股通增持金额前五个股分别为贵州茅台、中国建筑、山西汾酒、兴业银行、招商银行。百济神州-U近5个交易日下跌2.38%，沪股通累计增持24.74万股；近20个交易日下跌10.75%，沪股通累计增持128.51万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160935088781df2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160935088781df2d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427853720","title":"百济神州(06160)：建议授予董事受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2427853720","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427853720?lang=zh_cn&edition=full","pubTime":"2024-04-16 07:37","pubTimestamp":1713224265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，董事会已议决根据2016年计划建议授予受限制股份单位及业绩股份单位如下，但须获接纳及于股东周年大会上获独立股东批准方可作实：授予欧雷强先生于授予日期公平值为600万美元的受限制股份单位;授予欧雷强先生于授予日期公平值为600万美元的业绩股份单位;授予王晓东博士于授予日期公平值为133.33万美元的受限制股份单位;及授予各独立非执行董事于授予日期公平值为20万美元的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103026.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427921044","title":"百济神州（上海）生物科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2427921044","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427921044?lang=zh_cn&edition=full","pubTime":"2024-04-15 15:02","pubTimestamp":1713164560,"startTime":"0","endTime":"0","summary":"4月15日，据CDE官网消息，百济神州(上海)生物科技有限公司联合申请药品“替雷利珠单抗注射液”，获得临床试验默示许可，受理号CXSB2400009。公示信息显示，药品“替雷利珠单抗注射液”适应症：替雷利珠单抗联合Ociperlimab用于非小细胞肺癌的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415150523877e3b04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415150523877e3b04&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426692332","title":"百济神州下跌2.18%，报146.5美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426692332","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426692332?lang=zh_cn&edition=full","pubTime":"2024-04-11 22:56","pubTimestamp":1712847394,"startTime":"0","endTime":"0","summary":"4月11日，百济神州(BGNE)盘中下跌2.18%，截至22:56，报146.5美元/股，成交903.48万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/11225640205824.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426066224","title":"百济神州(06160)下跌5.04%，报88.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426066224","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426066224?lang=zh_cn&edition=full","pubTime":"2024-04-11 11:22","pubTimestamp":1712805723,"startTime":"0","endTime":"0","summary":"4月11日，百济神州(06160)盘中下跌5.04%，截至11:22，报88.5元/股，成交4451.78万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2023年年报，百济神州营业总收入174.15亿元、净利润-62.45亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/11112240195394.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426593406","title":"百济神州(06160)股价下跌5.043%，现价港币$88.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2426593406","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426593406?lang=zh_cn&edition=full","pubTime":"2024-04-11 11:20","pubTimestamp":1712805600,"startTime":"0","endTime":"0","summary":"[下跌股]百济神州(06160) 股价在上午11:20比前收市价下跌5.043%，现股价为港币$88.5。至目前为止，今日最高价为$90.6，而最低价为$88.5。总成交量为47.68万股，总成交金额为港币$4.272千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240411964/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2426048188","title":"《大行》美银证券降百济神州(06160.HK)目标价至99.21元  评级“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2426048188","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426048188?lang=zh_cn&edition=full","pubTime":"2024-04-10 12:01","pubTimestamp":1712721660,"startTime":"0","endTime":"0","summary":"美银证券发表研究报告指，百济神州自研药物帕米帕利2月销售额为60万元人民币，按年跌27.8%，按月跌43.2%，而替雷利珠单抗、Zanubrutinib的销售额则分别为1.609亿和4,470万元人民币，按年增长51.9%及26.4%，按月则降31%及32%。2月药品销售按月下降主要是受到农历新年的影响。该行表示，鉴于中国市场上PARP抑制剂和其他生物类似药产品的激烈竞争，将目标价由108.27元下调至99.21元，并重申“中性”评级。(港股报价延迟最少十五分钟。沽空资料截至 2024-04-09 16:25。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210201153351459_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210201153351459_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1341255/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2426105895","title":"百济神州-U4月9日获北向资金加仓25.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426105895","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426105895?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:30","pubTimestamp":1712712637,"startTime":"0","endTime":"0","summary":"4月9日, 北向资金增持百济神州-U25.15万股，连续4日增持。截止当日收盘，沪股通共持有百济神州-U531.61万股，占流通股4.62%。沪股通增持金额前五个股分别为紫金矿业、海尔智家、赤峰黄金、中金黄金、洛阳钼业。百济神州-U近5个交易日下跌1.30%，沪股通累计增持47.79万股；近20个交易日上涨2.97%，沪股通累计增持227.56万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100935168b064b35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100935168b064b35&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426113306","title":"百济神州上涨2.47%，报153.45美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426113306","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2426113306?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:21","pubTimestamp":1712672517,"startTime":"0","endTime":"0","summary":"转自：金融界本文源自:金融界4月9日，百济神州(BGNE)盘中上涨2.47%，截至22:00，报153.45美元/股，成交173.16万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：4月8日，百济神州获美国银行下调目标价至164.3美元，最新评级Neutral。5月2日，百济神州将披露2024财年一季报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404092222038b03bf94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404092222038b03bf94&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426184735","title":"肿瘤创新药“广州造”，粤港澳大湾区首个ADC生产基地启用","url":"https://stock-news.laohu8.com/highlight/detail?id=2426184735","media":"南方都市报","top":-1,"share":"https://www.laohu8.com/m/news/2426184735?lang=zh_cn&edition=full","pubTime":"2024-04-09 12:14","pubTimestamp":1712636046,"startTime":"0","endTime":"0","summary":"4月8日，创新药企百济神州位于中新广州知识城的广州大分子生物药生产基地抗体偶联药物生产园区竣工启用，这不仅是广州第一个、也是粤港澳大湾区的首个ADC生产基地。位于广州生物药生产基地南园的ADC生产园区，占地5.8万平方米，将成为百济神州ADC药物研发和生产的核心基地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091215578b0141dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091215578b0141dc&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.0369},{"period":"1month","weight":-0.0857},{"period":"3month","weight":-0.1351},{"period":"6month","weight":-0.162},{"period":"1year","weight":-0.46},{"period":"ytd","weight":-0.2294}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.0417},{"period":"6month","weight":0.2257},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.018078},{"month":5,"riseRate":0.5,"avgChangeRate":-0.012888},{"month":6,"riseRate":0.625,"avgChangeRate":0.022561},{"month":7,"riseRate":0.75,"avgChangeRate":0.132564},{"month":8,"riseRate":0.5,"avgChangeRate":0.021799},{"month":9,"riseRate":0.5,"avgChangeRate":0.051436},{"month":10,"riseRate":0.625,"avgChangeRate":0.017618},{"month":11,"riseRate":0.5,"avgChangeRate":0.059889},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}